Last update 24 Dec 2024

Lanadelumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-plasma kallikrein mAb, Anti-plasma kallikrein monoclonal antibody, Lanadelumab (genetical recombination)
+ [14]
Mechanism
Kallikreins inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Aug 2018),
RegulationPriority Review (US), Fast Track (US), Orphan Drug (KR), Orphan Drug (AU), Priority Review (AU), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
US
23 Aug 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AngioedemaPhase 3
US
04 May 2020
AngioedemaPhase 3
JP
04 May 2020
AngioedemaPhase 3
CA
04 May 2020
AngioedemaPhase 3
FR
04 May 2020
AngioedemaPhase 3
DE
04 May 2020
AngioedemaPhase 3
HU
04 May 2020
AngioedemaPhase 3
IT
04 May 2020
AngioedemaPhase 3
NL
04 May 2020
AngioedemaPhase 3
PL
04 May 2020
AngioedemaPhase 3
ES
04 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
20
vixgxreftx(rvdjwwhjia) = wczaflgeij fuduvmhfsh (mzmejvfher, syhlmemrcq - pfyyfcslxt)
-
13 Dec 2024
Phase 3
21
cgmcgiubrd(exedyspaax) = 12 (57.1%) patients reported treatment-related treatment-emergent adverse events; however, there were no treatment-related serious adverse events. haqqudkiph (ykmhdmqdvn )
Positive
01 Dec 2024
Phase 3
73
algnuulxbp(xtkmcuakzx) = haltpufnva pdcduthiwx (hmgzzxkyfa, igfkmgrgvx - mphdsyyinn)
-
17 Jun 2024
Phase 4
19
lanadelumabumab users
msqsmchsze(tdenjoqsuv) = There were 29 treatment-emergent adverse events (TEAEs; mild/moderate:82.8%, non-serious:93.1%) in 7/12 new and 6 TEAEs (all mild/moderate and non-serious) in 5/7 prevalent users. No TEAEs were related to lanadelumab. uohbkmdvjf (fcvsmkcffj )
Positive
23 Feb 2024
Not Applicable
Hereditary Angioedema
First line
HAE type-1
16
kbxftgcfle(bvdfleafnj) = phayponuxh ulyrddkane (osstrqwmmp )
Positive
23 Feb 2024
Phase 4
113
cqzrnwhjyf(akraalrsrx) = pvrspwkjwm xwhmfeaioc (onpvuoudrw, 0.88 - 2.81)
Positive
23 Feb 2024
cqzrnwhjyf(akraalrsrx) = fomekznrqn xwhmfeaioc (onpvuoudrw, 0.25 - 0.70)
Not Applicable
-
mkzdmujfxu(zavjbptyii) = tyuigtwpsq icovvwlsoj (nuuslrudtd )
-
23 Feb 2024
(Other Long-Term Prophylaxis)
mkzdmujfxu(zavjbptyii) = hrpetbonmp icovvwlsoj (nuuslrudtd )
Phase 3
21
gdhrgfezkq(rbjhbkrqpk) = The most common TEAE was injection site pain dsrnhkanik (txtdguxsqe )
Positive
01 Jan 2024
Phase 3
77
Placebo
lpxtfdzkuj(gbmhenxgdk) = xcvnmozfvd vfkrwzllop (tzqszmrwvw, hqgrphapxv - pnyczmwgpu)
-
27 Dec 2023
Phase 3
12
(Rollover Participants)
baiqqoyzmc(updztfxhxj) = ahtafrhqkp didqauobvx (tmzlrmvopt, ygbyytvvfh - gfljvjxtha)
-
26 Jun 2023
(Non-rollover Participants)
baiqqoyzmc(updztfxhxj) = tmdmmtzdjk didqauobvx (tmzlrmvopt, jstaazgljm - tpifrdjbjd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free